Skip to content

Serotonin research published in 2023

Page 2 of 5: studies 21 to 40 of 91, newest first. Back to the serotonin overview

Studies

Mephedrone induces partial release at human dopamine transporters but full release at human serotonin transporters

Neuropharmacology September 11, 2023 Felix P. Mayer, Marco Niello, Simon Bulling et al. 4 citations

Mephedrone (4-methylmethcathinone) is a cathinone derivative that is recreationally consumed for its energizing and empathogenic effects. The stimulating properties are believed to arise from the ability of mephedrone to interact with the high-affinity transporters for dopamine (DA) (DAT) and norepinephrine (NET), whereas the entactogenic effect presumably relies on its activity at the...

Molecular and structural insights into the 5‐HT2C receptor as a therapeutic target for substance use disorders

British Journal of Pharmacology September 8, 2023 Maleesha Ubhayarathna, Christopher J. Langmead, Natalie Diepenhorst et al. 10 citations

Abstract Substance use disorder (SUD) is a chronic condition, with maintained abuse of a substance leading to physiological and psychological alterations and often changes in cognitive and social behaviours. Current therapies include psychotherapy coupled with medication; however, high relapse rates reveal the shortcomings of these therapies. The signalling, expression profile, and neurological...

DOI: 10.1111/bph.16233 (opens in new tab) Serotonin Context archaeology 5-ht2c receptor Functional selectivity +4

Central nervous system activity of a Tabernaemontana arborea alkaloid extract involves serotonergic and opioidergic neurotransmission in murine models.

Fitoterapia September 1, 2023 M E González-trujano, N Páez-martínez, Felix Krengel et al. 4 citations

Tabernaemontana arborea (Apocynaceae) is a Mexican tree species known to contain ibogan type alkaloids. This study aimed at determining central nervous system-related activities of an alkaloid extract obtained from the root bark of T. arborea. A gas chromatography-mass spectrometry (GC-MS) analysis was performed to describe the alkaloid profile of the extract. A wide dosing range (0.1 to 56.2...

DOI: 10.1016/j.fitote.2023.105602 (opens in new tab) Full text (opens in new tab) Antidepressant-like activity Antinociceptive Memory impairment Tabernaemontana phytochemistry: tabernaemontana +13

Molecular insights into GPCR mechanisms for drugs of abuse.

Journal of Biological Chemistry September 1, 2023 Omar B Sanchez-Reyes, Gregory Zilberg, John D. Mccorvy et al. 10 citations

Substance abuse is on the rise, and while many people may use illicit drugs mainly due to their rewarding effects, their societal impact can range from severe, as is the case for opioids, to promising, as is the case for psychedelics. Common with all these drugs' mechanisms of action are G protein-coupled receptors (GPCRs), which lie at the center of how these drugs mediate inebriation,...

The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits

Journal of Applied Toxicology August 30, 2023 Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet et al. 2 citations

Abstract Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these...

Pharmacology and Therapeutic Effects of Psilocybin

Highlights in Science, Engineering and Technology August 29, 2023 Xuehan Du 1 citation

Psilocybin, a psychoactive alkaloid with hallucinogenic properties, exists in a variety of hallucinogenic mushrooms. As a study tool to imitate psychosis, psilocybin has aroused a lot of interest in the biological community due to its various possible therapeutic benefits. It is also a very popular and widely misused natural hallucinogens with distinct metabolism pathways and toxicity. In this...

Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents

Expert Opinion on Drug Safety August 28, 2023 Roger S McIntyre 16 citations

KEYWORDS: Psychedelicpsilocybinlysergic acid diethylamidemood disordersantidepressantsdiscoverypharmacologyFDA

Molecular Docking Assessment of Cathinones as 5-HT2AR Ligands: Developing of Predictive Structure-Based Bioactive Conformations and Three-Dimensional Structure-Activity Relationships Models for Future Recognition of Abuse Drugs

Molecules August 24, 2023 Nevena Tomašević, Maja Vujović, E. Kostić et al. 5 citations

Commercially available cathinones are drugs of long-term abuse drugs whose pharmacology is fairly well understood. While their psychedelic effects are associated with 5-HT2AR, the enclosed study summarizes efforts to shed light on the pharmacodynamic profiles, not yet known at the receptor level, using molecular docking and three-dimensional quantitative structure–activity relationship (3-D...

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders

Journal of Psychoactive Drugs August 24, 2023 Stanley Wong, An Yi Yu, Nicholas Fabiano et al. 11 citations

There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics...

Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.

Scientific Reports August 17, 2023 Anne Buot, Cecile Pallares, Alina Oganesyan et al. 28 citations

A renewed interest in the use of psychedelics for treating obsessive compulsive disorder (OCD) has emerged in the last 20 years. But pre-clinical and clinical evidence remain scarce, and little is known about the factor determining the magnitude and persistence of the therapeutic effect. We therefore designed a retrospective online survey to explore, in the general population using psychoactive...

DOI: 10.1038/s41598-023-39812-0 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health OCD Treatment Therapeutic research +1

Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells

Current Issues in Molecular Biology August 15, 2023 Gregory Ian Robinson, Dongping Li, Bo Wang et al. 20 citations

Intestinal inflammation and dysbiosis can lead to inflammatory bowel diseases (IBD) and systemic inflammation, affecting multiple organs. Developing novel anti-inflammatory therapeutics is crucial for preventing IBD progression. Serotonin receptor type 2A (5-HT2A) ligands, including psilocybin (Psi), 4-Acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), and ketanserin (Ket), along with transient...

DOI: 10.3390/cimb45080427 (opens in new tab) Serotonin 5-HT Receptor Transient computer programming Cell biology +2

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Journal of Psychopharmacology August 12, 2023 Michael Tagen, Daniel Mantuani, Alex Holstein et al. 39 citations

Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This...

The Synergistic Effects of 5-HT2A and TRP Agonism/Antagonism in Reducing Inflammation for Enhanced Mental and Physical Health.

ACS Medicinal Chemistry Letters August 10, 2023 Robert B. Kargbo

Depression is a widespread issue in the United States and the leading cause of disability globally, impacting people of all ages. Although selective serotonin reuptake inhibitors (SSRIs) are commonly used for treatment, they have limited effectiveness and may take weeks to show results. There is a pressing need for fast and effective solutions for various types of depression, including chronic,...

Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists.

ACS Chemical Neuroscience August 2, 2023 Eline Pottie, Christian B M Poulie, Icaro A Simon et al. 25 citations

Serotonergic psychedelics are described to have activation of the serotonin 2A receptor (5-HT2A) as their main pharmacological action. Despite their relevance, the molecular mechanisms underlying the psychedelic effects induced by certain 5-HT2A agonists remain elusive. One of the proposed hypotheses is the occurrence of biased agonism, defined as the preferential activation of certain...

DOI: 10.1021/acschemneuro.3c00267 (opens in new tab) Full text (opens in new tab) 5-ht2a Biased agonism In vitro pharmacology Minigαq +6

Therapeutic effects of methimazole on 3,4-methylenedioxymethamphetamine-induced hyperthermia and serotonergic neurotoxicity.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie August 1, 2023 I-Hsun Li, Tsung-Ta Liu, Ying-Chen Chen et al.

3,4-methylenedioxymethamphetamine (MDMA) is a popular recreational drug, however over 200 studies demonstrate that acute (e.g. hyperthermia, rhabdomyolysis) and chronic (e.g. neurotoxicity) toxicity effects of MDMA were observed in different animals. Methimazole (MMI), an inhibitor of thyroid hormone synthesis, was found to significantly reduce the HSP72 expression of heat stress induced in...

Identification of 5-HT 2A Receptor Signaling Pathways Responsible for Psychedelic Potential

bioRxiv (Cold Spring Harbor Laboratory) July 31, 2023 Jason Wallach, Andrew B. Cao, Maggie M. Calkins et al. 11 citations preprint

Summary Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT 2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT 2A -Gq/11 and β-arrestin2 signaling, making their respective roles unclear. To elucidate this, we developed a series of 5-HT 2A -selective ligands with varying Gq efficacies, including β-arrestin-biased...

5-HT2AR and NMDAR psychedelics induce similar hyper-synchronous states in the rat cognitive-limbic cortex-basal ganglia system.

Communications Biology July 26, 2023 Ivani Brys, Sebastian A Barrientos, Jon Ezra Ward et al. 33 citations

The profound changes in perception and cognition induced by psychedelic drugs are thought to act on several levels, including increased glutamatergic activity, altered functional connectivity and an aberrant increase in high-frequency oscillations. To bridge these different levels of observation, we have here performed large-scale multi-structure recordings in freely behaving rats treated with...

DOI: 10.1038/s42003-023-05093-6 (opens in new tab) Full text (opens in new tab) Psychedelics Brain waves Consciousness Pharmacology

Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hour

Research Square July 18, 2023 Sanah Malomile Nkadimeng, L. Hay, Christiaan Ml Steinmann et al. 1 citation preprint

Abstract Background Psilocybin-containing mushrooms induce antidepressant and momentary increase in blood pressure (BP) with potential risk to users with cardiovascular diseases. Irregularities in nitric oxide (NO) levels play a key role in endothelial dysfunctions leading to increases in BP. Mushrooms species show large variation in potency which may potentially induce different outcomes and...

Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings

Frontiers in Human Neuroscience July 18, 2023 Nicolas Garel, Julien Thibault Lévesque, Dasha A. Sandra et al. 29 citations

Background Psychedelic drug experiences are shaped by current-moment contextual factors, commonly categorized as internal (set) and external (setting). Potential influences of past environments, however, have received little attention. Aims To investigate how previous environmental stimuli shaped the experiences of patients receiving ketamine for treatment-resistant depression (TRD), and...